News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Walvax Biotech Gains Majority Control of Fengmao Biotech


7/11/2012 8:12:24 AM

by Richard Daverman, PhD

July 10, 2012 -- Yunnan Walvax Biotechnology, a vaccine company, obtained a 51% stake in Shanghai Fengmao Biotechnology Co. Walvax will establish subsidiaries of Fengmao to produce five monoclonal antibodies and a sustained-release version of the anemia treatment EPO. Walvax will invest 102 million RMB ($16 million), in a combination of cash and technology, to obtain control of Fengmao. More details....

Stock Symbol: (SHE: 300142)


Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES